Register entry
Novartis Innovative Technologies Inc.
- Registered sites
- 1
- Drug products
- 38
- Live patents
- 0
- Countries
- 1
- Base
- United States
Authorisation
Registered operations
What the FDA has registered these sites to do. This is the regulatory record, not a marketing claim.
Analytical testingLabellingFinished drug manufacturePackaging
Sites
Facilities
1| Site | Location | Operations | FEI |
|---|---|---|---|
| Novartis Innovative Technologies Inc. | Durham, NCUnited States | Analytical testing, Labelling, Finished drug manufacture, Packaging | 3015404862 |
Catalogue
Marketed products
38Showing 38 of 38.
| Brand | Generic name | Form | Category |
|---|---|---|---|
| ITVISMA | onasemnogene abeparvovec-brve | INJECTION, SUSPENSION | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
| Zolgensma | onasemnogene abeparvovec-xioi | KIT | BLA |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.